Dysfunction of the MDM2/p53 axis is linked to premature aging

Journal of Clinical Investigation

Volumn 127, Issue 10, 2017, Pages 3598-3608

  Lessel, Davor ^a   Wu, Danyi ^b   Trujillo, Carlos ^c   Ramezani, Thomas ^d,l   Lessel, Ivana ^a   Alwasiyah, Mohammad K ^e   Saha, Bidisha ^f   Hisama, Fuki M ^g   Rading, Katrin ^a   Goebel, Ingrid ^a   Schütz, Petra ^h   Speit, Günter ^h   Högel, Josef ^h   Thiele, Holger ⁱ   Nürnberg, Gudrun ⁱ   Nürnberg, Peter ^d,i   Hammerschmidt, Matthias ^d   Zhu, Yan ^b,m   Tong, David R ^b   Katz, Chen ^b   Martin, George M ^f,j   Oshima, Junko ^f,k   Prives, Carol ^b   Kubisch, Christian ^a,h   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Dr Erfan and Bagedo Hospital ^*  (Saudi Arabia)

^d UNIVERSITY OF COLOGNE   (Germany)

^e MINISTRY OF HEALTH   (Saudi Arabia)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ULM   (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k CHIBA UNIVERSITY   (Japan)

^l UNIVERSITY OF EDINBURGH   (United Kingdom)

^m ST JOHN'S UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APHIDICOLIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DAUNORUBICIN; DOXORUBICIN; MITOMYCIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, ZEBRAFISH; TP53 PROTEIN, HUMAN; ZEBRAFISH PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; FEEDBACK SYSTEM; GERMLINE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NCI-H1299 CELL LINE; NONHUMAN; PREMATURE AGING; PRIMARY CELL; PRIORITY JOURNAL; PROGERIA; PROTEIN STABILITY; REGULATORY MECHANISM; U2OS CELL LINE; WERNER SYNDROME; ZEBRA FISH; ANIMAL; APOPTOSIS; DISEASE MODEL; GENETICS; METABOLISM; TUMOR CELL LINE;

AGING, PREMATURE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GERM-LINE MUTATION; HUMANS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 85030566610     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI92171     Document Type: Conference Paper

References (60)

1. Malkin D, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233-1238.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-310.
3. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413-431.
4. Krizhanovsky V, Lowe SW. Stem cells: The promises and perils of p53. Nature. 2009;460(7259):1085-1086.
5. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 2010;17(1):86-92.
6. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010;20(5):299-309.
7. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7(7A):1126-1132.
8. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993;12(2):461-468.
9. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8(4):275-283.
10. Zhang B, Golding BT, Hardcastle IR. Small-molecule MDM2-p53 inhibitors: recent advances. Future Med Chem. 2015;7(5):631-645.
11. Kulju KS, Lehman JM. Increased p53 protein associated with aging in human diploid fibroblasts. Exp Cell Res. 1995;217(2):336-345.
12. Feng Z, Hu W, Teresky AK, Hernando E, Cordon-Cardo C, Levine AJ. Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A. 2007;104(42):16633-16638.
13. Ørsted DD, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med. 2007;204(6):1295-1301.
14. Bergamaschi D, et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet. 2006;38(10):1133-1141.
15. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357-365.
16. van Heemst D, et al. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol. 2005;40(1-2):11-15.
17. Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science. 2006;312(5776):1059-1063.
18. Varela I, et al. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature. 2005;437(7058):564-568.
19. Tyner SD, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002;415(6867):45-53.
20. Maier B, et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 2004;18(3):306-319.
21. Liu D, et al. Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol. 2010;12(10):993-998.
22. Mendrysa SM, et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 2006;20(1):16-21.
23. García-Cao I, et al. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 2002;21(22):6225-6235.
24. Lessel D, et al. POLD1 Germline Mutations in Patients Initially Diagnosed with Werner Syndrome. Hum Mutat. 2015;36(11):1070-1079.
25. Poyurovsky MV, et al. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 2007;26(1):90-101.
26. Uldrijan S, Pannekoek WJ, Vousden KH. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J. 2007;26(1):102-112.
27. Dolezelova P, Cetkovska K, Vousden KH, Uldrijan S. Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers. Cell Cycle. 2012;11(5):953-962.
28. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69(7):1237-1245.
29. Purvis JE, Karhohs KW, Mock C, Batchelor E, Loewer A, Lahav G. p53 dynamics control cell fate. Science. 2012;336(6087):1440-1444.
30. Lessel D, et al. Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features. Nat Genet. 2014;46(11):1239-1244.
31. Tivey HS, Brook AJ, Rokicki MJ, Kipling D, Davis T. p38 (MAPK) stress signalling in replicative senescence in fibroblasts from progeroid and genomic instability syndromes. Biogerontology. 2013;14(1):47-62.
32. Langheinrich U, Hennen E, Stott G, Vacun G. Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling. Curr Biol. 2002;12(23):2023-2028.
33. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14(5):359-370.
34. Khoo KH, Hoe KK, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014;13(3):217-236.
35. Zhang Q, Zeng SX, Lu H. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 2014;85:281-319.
36. Andreeff M, et al. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res. 2016;22(4):868-876.
37. Wagner AJ, et al. Phase I trial of the human double minute 2 inhibitor MK-8242 in patients with advanced solid tumors. J Clin Oncol. 2017;35(12):1304-1311.
38. Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med. 2014;211(11):2137-2149.
39. Moore L, Lu X, Ghebranious N, Tyner S, Donehower LA. Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Mech Ageing Dev. 2007;128(11-12):717-730.
40. Donehower LA. Using mice to examine p53 functions in cancer, aging, and longevity. Cold Spring Harb Perspect Biol. 2009;1(6):a001081.
41. Matheu A, et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature. 2007;448(7151):375-379.
42. Gannon HS, Donehower LA, Lyle S, Jones SN. Mdm2-p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin. Dev Biol. 2011;353(1):1-9.
43. Itahana K, et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell. 2007;12(4):355-366.
44. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378(6553):206-208.
45. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378(6553):203-206.
46. Tollini LA, Jin A, Park J, Zhang Y. Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage. Cancer Cell. 2014;26(2):235-247.
47. Latini P, et al. CSA and CSB proteins interact with p53 and regulate its Mdm2-dependent ubiquitination. Cell Cycle. 2011;10(21):3719-3730.
48. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-1217.
49. Poyurovsky MV, Prives C. P53 and aging: A fresh look at an old paradigm. Aging (Albany NY). 2010;2(7):380-382.
50. Campisi J. Fragile fugue: p53 in aging, cancer and IGF signaling. Nat Med. 2004;10(3):231-232.
51. Li Q, Lozano G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res. 2013;19(1):34-41.
52. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene. 2007;26(9):1306-1316.
53. Hilliard SA, Yao X, El-Dahr SS. Mdm2 is required for maintenance of the nephrogenic niche. Dev Biol. 2014;387(1):1-14.
54. Mulay SR, Thomasova D, Ryu M, Anders HJ. MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice. Kidney Int. 2012;81(12):1199-1211.
55. El-Dahr S, Hilliard S, Aboudehen K, Saifudeen Z. The MDM2-p53 pathway: multiple roles in kidney development. Pediatr Nephrol. 2014;29(4):621-627.
56. Martin GM. Genetic syndromes in man with potential relevance to the pathobiology of aging. Birth Defects Orig Artic Ser. 1978;14(1):5-39.
57. Huang S, et al. The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat. 2006;27(6):558-567.
58. Seelow D, et al. Homozygosity Mapper-an interactive approach to homozygosity mapping. Nucleic Acids Res. 2009;37(Suppl 2):W593-W599.
59. Parant JM, George SA, Holden JA, Yost HJ. Genetic modeling of Li-Fraumeni syndrome in zebrafish. Dis Model Mech. 2010;3(1-2):45-56.
60. Cole LK, Ross LS. Apoptosis in the developing zebrafish embryo. Dev Biol. 2001;240(1):123-142.